OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
April 23, 2019 08:00 ET
|
OmniSeq
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global...
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
July 31, 2018 16:05 ET
|
OmniSeq
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
April 12, 2018 09:00 ET
|
OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
November 09, 2017 08:02 ET
|
OmniSeq
BUFFALO, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of Roswell Park Cancer Institute, announced today that it received accreditation by the College of...
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
August 21, 2017 08:01 ET
|
OmniSeq
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered into an exclusive...
OmniSeq Launches Immune Report Card
June 14, 2017 08:05 ET
|
OmniSeq
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling...